# High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

> **NCT02597062** · PHASE2 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 76 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02597062
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-05
- **Primary completion:** 2019-06-19
- **Final completion:** 2022-02-01
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2023-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597062, "High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02597062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*